(TXG) 10X Genomics - Ratings and Ratios
Single Cell Sequencing, Spatial Gene Mapping, ATAC Technology
TXG EPS (Earnings per Share)
TXG Revenue
Description: TXG 10X Genomics
10X Genomics Inc (NASDAQ:TXG) is a life sciences company that operates in the tools and services sub-industry. The companys stock is listed on the NASDAQ exchange and has a market capitalization of $1.51 billion.
The stocks recent price action has been volatile, with a beta of 2.028 indicating high sensitivity to market fluctuations. Key drivers of the stocks performance include revenue growth, driven by the adoption of its innovative genomics solutions, and the companys ability to expand its customer base and increase sales of its products and services.
From a fundamental perspective, the companys forward P/E ratio of 196.08 suggests that investors are expecting significant future growth. However, the current return on equity (ROE) of -21.93% indicates that the company is currently unprofitable. Key performance indicators (KPIs) to watch include revenue growth rate, gross margin expansion, and operating expense management.
Economic drivers that may impact TXGs performance include the overall demand for life sciences tools and services, advancements in genomics and related technologies, and the competitive landscape. The companys ability to innovate and bring new products to market, as well as its ability to manage costs and achieve scale, will be critical to its future success.
Investors should also monitor the companys cash burn rate, as well as its ability to generate cash from operations, as these will be important indicators of its ability to achieve profitability and sustain its business model.
TXG Stock Overview
| Market Cap in USD | 1,661m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2019-09-12 |
TXG Stock Ratings
| Growth Rating | -75.7% |
| Fundamental | 44.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -49.3% |
| Analyst Rating | 3.75 of 5 |
TXG Dividends
Currently no dividends paidTXG Growth Ratios
| Growth Correlation 3m | 63% |
| Growth Correlation 12m | -59.4% |
| Growth Correlation 5y | -90.1% |
| CAGR 5y | -24.99% |
| CAGR/Max DD 3y | -0.28 |
| CAGR/Mean DD 3y | -0.59 |
| Sharpe Ratio 12m | -0.31 |
| Alpha | 0.00 |
| Beta | 0.982 |
| Volatility | 58.51% |
| Current Volume | 2265.6k |
| Average Volume 20d | 2278k |
| Stop Loss | 12.1 (-5.9%) |
| Signal | -1.24 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-84.6m TTM) > 0 and > 6% of Revenue (6% = 38.7m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 12.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 84.32% (prev 74.10%; Δ 10.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 67.0m > Net Income -84.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (124.5m) change vs 12m ago 3.70% (target <= -2.0% for YES) |
| Gross Margin 69.50% (prev 63.96%; Δ 5.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.50% (prev 67.95%; Δ -0.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7304 (EBITDA TTM -54.2m / Interest Expense TTM 13.0k) >= 6 (WARN >= 3) |
Altman Z'' -9.36
| (A) 0.55 = (Total Current Assets 655.7m - Total Current Liabilities 112.2m) / Total Assets 980.0m |
| (B) -1.50 = Retained Earnings (Balance) -1.47b / Total Assets 980.0m |
| warn (B) unusual magnitude: -1.50 — check mapping/units |
| (C) -0.10 = EBIT TTM -95.0m / Avg Total Assets 954.8m |
| (D) -7.10 = Book Value of Equity -1.47b / Total Liabilities 206.7m |
| Total Rating: -9.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.86
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 4.32% = 2.16 |
| 3. FCF Margin 8.83% = 2.21 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -1.92 = -2.50 |
| 6. ROIC - WACC (= -22.11)% = -12.50 |
| 7. RoE -11.62% = -1.94 |
| 8. Rev. Trend 55.53% = 4.17 |
| 9. EPS Trend 55.58% = 2.78 |
What is the price of TXG shares?
Over the past week, the price has changed by +2.14%, over one month by -4.46%, over three months by +21.78% and over the past year by -39.93%.
Is 10X Genomics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TXG is around 10.02 USD . This means that TXG is currently overvalued and has a potential downside of -22.08%.
Is TXG a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TXG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.1 | 17.3% |
| Analysts Target Price | 15.1 | 17.3% |
| ValueRay Target Price | 11.2 | -12.7% |
Last update: 2025-09-05 05:05
TXG Fundamental Data Overview
CCE Cash And Equivalents = 447.3m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 196.0784
P/S = 2.5769
P/B = 2.146
Beta = 2.028
Revenue TTM = 644.5m USD
EBIT TTM = -95.0m USD
EBITDA TTM = -54.2m USD
Long Term Debt = 94.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 9.67m USD (from shortTermDebt, last quarter)
Debt = 104.1m USD (Calculated: Short Term 9.67m + Long Term 94.5m)
Net Debt = -311.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.32b USD (1.66b + Debt 104.1m - CCE 447.3m)
Interest Coverage Ratio = -7304 (Ebit TTM -95.0m / Interest Expense TTM 13.0k)
FCF Yield = 4.32% (FCF TTM 56.9m / Enterprise Value 1.32b)
FCF Margin = 8.83% (FCF TTM 56.9m / Revenue TTM 644.5m)
Net Margin = -13.13% (Net Income TTM -84.6m / Revenue TTM 644.5m)
Gross Margin = 69.50% ((Revenue TTM 644.5m - Cost of Revenue TTM 196.6m) / Revenue TTM)
Tobins Q-Ratio = -0.90 (set to none) (Enterprise Value 1.32b / Book Value Of Equity -1.47b)
Interest Expense / Debt = 0.00% (Interest Expense 3000 / Debt 104.1m)
Taxrate = 6.65% (2.46m / 37.0m)
NOPAT = -95.0m (EBIT -95.0m, no tax applied on loss)
Current Ratio = 5.84 (Total Current Assets 655.7m / Total Current Liabilities 112.2m)
Debt / Equity = 0.13 (Debt 104.1m / last Quarter total Stockholder Equity 773.3m)
Debt / EBITDA = -1.92 (Net Debt -311.0m / EBITDA -54.2m)
Debt / FCF = 1.83 (Debt 104.1m / FCF TTM 56.9m)
Total Stockholder Equity = 728.3m (last 4 quarters mean)
RoA = -8.63% (Net Income -84.6m, Total Assets 980.0m )
RoE = -11.62% (Net Income TTM -84.6m / Total Stockholder Equity 728.3m)
RoCE = -11.54% (Ebit -95.0m / (Equity 728.3m + L.T.Debt 94.5m))
RoIC = -13.04% (NOPAT -95.0m / Invested Capital 728.3m)
WACC = 9.07% (E(1.66b)/V(1.76b) * Re(9.64%)) + (D(104.1m)/V(1.76b) * Rd(0.00%) * (1-Tc(0.07)))
Shares Correlation 3-Years: 100.00 | Cagr: 0.80%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.60% ; FCFE base≈56.9m ; Y1≈37.3m ; Y5≈17.1m
Fair Price DCF = 2.30 (DCF Value 262.9m / Shares Outstanding 114.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 55.58 | EPS CAGR: 38.11% | SUE: 3.13 | # QB: 2
Revenue Correlation: 55.53 | Revenue CAGR: 10.60% | SUE: N/A | # QB: None
Additional Sources for TXG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle